Onyx Biotec promoter Sanjay Jain reduced his shareholding by 9.78% through the sale of 1,774,000 equity shares on the National Stock Exchange (NSE) on May 29, 2026. The disposal, valued at ₹5,43,55,360, was disclosed to the company under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Following the transaction, Jain's holding in the pharmaceutical company decreased from 21.48% to 11.70%.

The disclosure was submitted in Form C to Onyx Biotec on May 29, 2026, and subsequently forwarded to the National Stock Exchange of India Limited on May 30, 2026. The filing confirmed that the trade was executed on the market, with no activity reported in the derivatives segment by the promoter.

Transaction Details

The sale involved a significant portion of Jain's equity, executed entirely through the open market mechanism. The transaction details, as per the filing, are outlined below:

The company, represented by CEO/CFO/WTB Harsh Mahajan, disseminated the information to the exchange to ensure compliance with regulatory requirements. The filing noted that the transaction value excludes taxes, brokerage, and other associated charges.

Onyx Biotec Ltd has announced the resignation of its Managing Director, Sanjay Jain, and Whole Time Director, Lakshya Jain, effective from the close of business hours on May 27, 2026. The decision was taken by the Board of Directors at its meeting held on May 25, 2026, based on the recommendation of the Nomination and Remuneration Committee. This leadership transition impacts the company's executive structure and committee composition, as Sanjay Jain will also cease to be a member of the Stakeholders' Relationship Committee following his departure.

Sanjay Jain cited health considerations and the increasing demands associated with age as the primary reasons for stepping down. In his resignation letter dated May 26, 2026, he stated that these factors make it difficult for him to continue discharging the responsibilities of the office with the required energy and attention. He confirmed that there are no other material reasons for his resignation and pledged to extend all reasonable assistance for a smooth transition and completion of necessary handover formalities.

Lakshya Jain resigned to pursue opportunities involving higher-risk exploration and experimentation, which he noted are better undertaken outside a public company. He stated that this decision aligns with his long-term professional goals and personal commitments. Similar to the Managing Director, he confirmed that there are no other material reasons for his resignation apart from those stated in his letter dated May 26, 2026.

The company disclosed that the resignations are pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The requisite disclosures under Regulation 30 read with Part A of Schedule III of the Listing Regulations and the relevant SEBI master circular have been submitted to the exchanges. The filing confirmed the familial relationship between the departing directors, noting that Sanjay Jain is the father of Lakshya Jain.

The following table details the particulars of the resignations as disclosed in the regulatory filing:

The Board meeting, where these resignations were considered, commenced at 4.00 p.m. and concluded at 4:15 p.m. on May 25, 2026. The company has requested the stock exchanges to update the information in their records and the Corporate Information Section.